Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
26509 | MYOF | GSM5353224_PA_PR5186_Pool_1_2_3_S27_L001 | Human | Prostate | Tumor | 1.60e-03 | 4.42e-01 | 0.1621 |
26509 | MYOF | GSM5353225_PA_PR5196-1_Pool_1_2_3_S53_L002 | Human | Prostate | Tumor | 3.37e-07 | 5.29e-01 | 0.1619 |
26509 | MYOF | GSM5353227_PA_PR5199-193K_Pool_1_2_3_S55_L002 | Human | Prostate | Tumor | 4.71e-20 | 8.31e-01 | 0.1602 |
26509 | MYOF | GSM5353228_PA_PR5199-640K_Pool_1_3_S108_L004 | Human | Prostate | Tumor | 1.09e-08 | 7.68e-01 | 0.1537 |
26509 | MYOF | GSM5353236_PA_PR5251_T1_S7_L001 | Human | Prostate | Tumor | 1.17e-04 | 4.64e-01 | 0.1608 |
26509 | MYOF | GSM5353237_PA_PR5251_T2_S8_L001 | Human | Prostate | Tumor | 1.09e-05 | 7.45e-01 | 0.1622 |
26509 | MYOF | GSM5353240_PA_PR5254_T1_S15_L001 | Human | Prostate | Tumor | 1.22e-16 | 6.07e-01 | 0.1575 |
26509 | MYOF | GSM5353243_PA_PR5261_T1_S23_L002 | Human | Prostate | Tumor | 2.91e-21 | 6.53e-01 | 0.1545 |
26509 | MYOF | GSM5353244_PA_PR5261_T2_S24_L002 | Human | Prostate | Tumor | 1.56e-17 | 6.15e-01 | 0.1569 |
26509 | MYOF | GSM5353247_PA_PR5269_3_S27_L002 | Human | Prostate | Tumor | 2.31e-07 | 7.70e-01 | 0.1532 |
26509 | MYOF | P1_S1_AK | Human | Skin | AK | 7.41e-16 | 5.06e-01 | -0.3399 |
26509 | MYOF | P2_S3_AK | Human | Skin | AK | 1.74e-06 | 2.94e-01 | -0.3287 |
26509 | MYOF | P2_S4_SCCIS | Human | Skin | SCCIS | 1.31e-02 | 2.17e-01 | -0.3043 |
26509 | MYOF | P3_S6_AK | Human | Skin | AK | 8.99e-09 | 4.35e-01 | -0.3256 |
26509 | MYOF | P4_S8_cSCC | Human | Skin | cSCC | 5.59e-14 | 3.21e-01 | -0.3095 |
26509 | MYOF | P5_S10_cSCC | Human | Skin | cSCC | 2.31e-12 | 3.26e-01 | -0.299 |
26509 | MYOF | P1_cSCC | Human | Skin | cSCC | 6.35e-28 | 9.14e-01 | 0.0292 |
26509 | MYOF | P2_cSCC | Human | Skin | cSCC | 3.52e-13 | 4.08e-01 | -0.024 |
26509 | MYOF | P4_cSCC | Human | Skin | cSCC | 4.23e-21 | 5.26e-01 | -0.00290000000000005 |
26509 | MYOF | P10_cSCC | Human | Skin | cSCC | 1.80e-17 | 6.04e-01 | 0.1017 |
Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/MYOF_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/MYOF_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/MYOF_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/MYOF_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MYOF_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/MYOF_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/MYOF_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/MYOF_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/MYOF_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/MYOF_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MYOF | SNV | Missense_Mutation | novel | c.1168N>C | p.Asp390His | p.D390H | Q9NZM1 | protein_coding | deleterious(0.01) | probably_damaging(0.975) | TCGA-A7-A6VY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
MYOF | SNV | Missense_Mutation | rs557119618 | c.409N>A | p.Gly137Arg | p.G137R | Q9NZM1 | protein_coding | tolerated(0.26) | possibly_damaging(0.587) | TCGA-A8-A09I-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
MYOF | SNV | Missense_Mutation | rs543442746 | c.3424N>T | p.Arg1142Cys | p.R1142C | Q9NZM1 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MYOF | SNV | Missense_Mutation | novel | c.1682N>G | p.Asp561Gly | p.D561G | Q9NZM1 | protein_coding | deleterious(0) | benign(0.301) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MYOF | SNV | Missense_Mutation | | c.5507N>C | p.Arg1836Thr | p.R1836T | Q9NZM1 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MYOF | SNV | Missense_Mutation | rs369733924 | c.6088G>A | p.Gly2030Ser | p.G2030S | Q9NZM1 | protein_coding | tolerated(0.26) | benign(0.132) | TCGA-E9-A1NA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
MYOF | SNV | Missense_Mutation | | c.5757N>G | p.Cys1919Trp | p.C1919W | Q9NZM1 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-E9-A244-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
MYOF | SNV | Missense_Mutation | novel | c.4985N>G | p.Ser1662Cys | p.S1662C | Q9NZM1 | protein_coding | deleterious(0.01) | possibly_damaging(0.653) | TCGA-E9-A3X8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphane | CR |
MYOF | SNV | Missense_Mutation | | c.2564G>C | p.Gly855Ala | p.G855A | Q9NZM1 | protein_coding | tolerated(0.06) | probably_damaging(0.999) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
MYOF | insertion | Nonsense_Mutation | novel | c.4612_4613insTATGAGTCCAGATATTACAGAGAGTCCTTGAGTGCTTGTGTGTT | p.Pro1538LeufsTer2 | p.P1538Lfs*2 | Q9NZM1 | protein_coding | | | TCGA-AN-A0FF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |